Abbott Rapid DX North America Awarded $760,000,000 Contract For BinaxNOW
Abbott Rapid DX North America LLC Orlando, Florida, has been awarded a firm-fixed-price, indefinite-delivery/indefinite-quantity contract for the production and delivery of BinaxNOW rapid point-of-care antigen tests for COVID-19.
The initial order is valued at $760,000,000 for 150 million tests and distribution costs. This was a sole-source acquisition to meet an urgent and compelling national need. An Emergency Use Authorization has been approved and signed by the Food and Drug Administration for this contract award. This is a four-month contract with no option periods. Locations of performance are Florida and Maine, with a Dec. 31, 2020, ordering period end date. Using customer is the Department of Health and Human Services. The maximum dollar value on the contract is $1,500,000,000. Type of appropriation is fiscal 2020 CARES Act funding. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-20-D-0027). (Awarded Aug. 27, 2020)
Abbott Rapid Dx North America, LLC is located in Orlando, FL, United States and is part of the Medical Equipment & Supplies Manufacturing Industry. Abbott Rapid Dx North America, LLC has 100 total employees across all of its locations and generates $23.11 million in sales (USD). There are 947 companies in the Abbott Rapid Dx North America, LLC corporate family. (www.dnb.com)